TOFAJAK 5MG TABLET contains Tofacitinib, which belongs to the group of medicines called Antirheumatics. It is used to manage inflammatory diseases such as rheumatoid arthritis (chronic inflammatory diseases affecting the joints, causing pain and swelling), psoriatic arthritis (an arthritic condition that occurs in an individual with psoriasis), ulcerative colitis (ulcerative inflammation of the digestive tract) and ankylosing spondylitis (fusion of bones in the spine).
TOFAJAK 5MG TABLET is also used to manage polyarticular juvenile idiopathic arthritis and juvenile psoriatic arthritis, which cause pain and inflammation of joints in children. TOFAJAK 5MG TABLET is used alone or together with other drugs, such as methotrexate.
TOFAJAK 5MG TABLET is not recommended for use in patients with severe liver diseases (including cirrhosis), bloodstream infections or active tuberculosis. TOFAJAK 5MG TABLET should be used with caution in patients who have an infection or a condition that increases their risk of infection (for example, diabetes, HIV/AIDS or a weak immune system), chronic lung disease, tuberculosis, hepatitis B or C, liver, kidney or heart diseases, cancer or are at risk of developing skin cancer, smoking habits, lactose intolerance, inflammation of the large intestine, stomach or intestine ulcers, blood pressure, high cholesterol or at risk of developing a blood clot, are planning to get vaccinated, have undergone major surgery.
TOFAJAK 5MG TABLET should not be used by pregnant or breastfeeding women. TOFAJAK 5MG TABLET should be used with caution in patients over the age of 65. The safety and effectiveness of TOFAJAK 5MG TABLET in children under the age of two have not yet been established.
Lung infection, sore throat, sinusitis, vomiting, nausea, diarrhoea, indigestion and headache are the most common side effects of TOFAJAK 5MG TABLET. Ask for your doctor’s advice if any of these worsen or don’t improve.
No content available
